Streetbeat News

LXRX

Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com

Industry

Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Open

0.36

Mkt cap

132M

Volume

5M

High

0.37

P/E Ratio

-0.58

52-wk high

2.59

Low

0.36

Div yield

N/A

52-wk low

0.28

Needham analyst Joseph Stringer has reiterated a Hold rating on Lexicon Pharmaceuticals (NASDAQ:LXRX), indicating no change in the firm's stance towards the stock.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 10:20 am

Cintas Corporation reported better-than-expected Q3 financial results, leading to a 9.7% rise in its shares. Other companies like PaySign, Noah Holdings, and NuScale Power also saw significant gains after positive financial reports or upgrades. Notably, Merck received FDA approval for a new treatment, contributing to a 4.4% increase in its stock price.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 2:03 pm

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced four presentations on sotagliflozin at the American College of Cardiology session, highlighting its efficacy in reducing stroke and heart attack risk among patients with type 2 diabetes, CKD, and high CV risk. The FDA approved sotagliflozin in 2023 for reducing cardiovascular death and hospitalization in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 1:25 pm

ACADIA Pharmaceuticals' shares fell sharply in pre-market trading after its Phase 3 trial for schizophrenia treatment failed to meet the primary endpoint. Other stocks like Ocular Therapeutix, Aeva Technologies, and Asana also saw declines due to various reasons including poor financial results and reverse stock split announcements.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 9:36 am

U.S. stocks showed mixed performance with the Dow Jones index rising slightly, while the NASDAQ and S&P 500 fell. Materials shares led gains, while industrials lagged. EQT Corporation announced a merger with Equitrans Midstream Corporation. GDS Holdings, Fangdd Network Group, and Lexicon Pharmaceuticals saw significant stock increases following positive news. Conversely, Eltek, Genie Energy, and Ventyx Biosciences experienced notable declines. Oil prices dipped slightly, while gold and silver saw gains.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 6:44 pm

Mesoblast Limited's shares surged by 13.4% after announcing FDA support for an accelerated approval pathway for rexlemestrocel-L. Other stocks also saw significant movements, with Kidpik Corp. leading the gainers with a 238% increase following a reverse stock split announcement. On the losers' side, Jeffs' Brands Ltd dropped by 45.2%. The market movements were influenced by various factors including FDA approvals, strategic plans, financial results expectations, and investment proposals.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 5:41 pm

U.S. stocks traded lower with the Dow Jones, NASDAQ, and S&P 500 all seeing declines. Materials shares rose, while industrials fell. EQT Corporation announced a merger with Equitrans Midstream Corporation. GDS Holdings, Fangdd Network Group, and Lexicon Pharmaceuticals saw significant stock increases, while Eltek, Genie Energy, and Ventyx Biosciences experienced declines. Oil and gold prices edged higher.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 4:15 pm

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 earnings, beating estimates with an EPS of $-0.2 against an expected $-0.22. Revenue increased by $674k from the previous year. Despite beating this quarter's estimates, a miss in the last quarter's EPS led to a 9% share price drop the following day. Historical earnings performance shows mixed results over the past quarters.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 2:00 pm

Lexicon Pharmaceuticals' shares surged after the company announced plans to resubmit its Sotagliflozin NDA for Type 1 diabetes based on FDA feedback. Furthermore, Lexicon revealed a securities purchase agreement anticipated to generate approximately $250 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:22 am

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 earnings with losses of $(0.20) per share, surpassing the consensus estimate of $(0.22) by 9.09%. This represents a 25% increase in losses compared to the same period last year. The company's cash position stands at $170M.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:17 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.